Boston Common Asset Management LLC Sells 2,435 Shares of Novo Nordisk A/S $NVO

Boston Common Asset Management LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 83,752 shares of the company’s stock after selling 2,435 shares during the period. Boston Common Asset Management LLC’s holdings in Novo Nordisk A/S were worth $5,781,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in NVO. Kingstone Capital Partners Texas LLC lifted its holdings in Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after purchasing an additional 10,001,898 shares during the last quarter. Nuveen LLC bought a new position in Novo Nordisk A/S during the 1st quarter valued at about $370,272,000. Amundi lifted its holdings in Novo Nordisk A/S by 49.1% during the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock valued at $331,576,000 after purchasing an additional 1,627,051 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Novo Nordisk A/S by 15,919.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock valued at $72,523,000 after purchasing an additional 1,038,137 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Novo Nordisk A/S by 118.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,594,544 shares of the company’s stock valued at $110,725,000 after purchasing an additional 864,579 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Up 1.6%

Shares of NYSE NVO opened at $59.68 on Friday. The stock has a market cap of $266.45 billion, a P/E ratio of 16.39, a P/E/G ratio of 2.28 and a beta of 0.68. The firm has a 50 day moving average price of $54.92 and a 200 day moving average price of $63.73. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $120.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s payout ratio is currently 22.53%.

Analyst Ratings Changes

Several brokerages recently issued reports on NVO. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. TD Cowen dropped their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 19th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Morgan Stanley downgraded shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their target price for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Novo Nordisk A/S in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $77.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.